Routine thyroid cancer screening among asymptomatic patients does not offer any benefit for patients.
The U.S. Preventive Services Task Force (USPSTF) does not recommend routine thyroid cancer screening among adults who are asymptomatic, according to a statement published in the Journal of the American Medical Association. The USPSTF reviewed the evidence on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic accuracy of screening (including neck palpation and ultrasound), and the benefits and harms of treatment of screen-detected thyroid cancer. The rate of increase in thyroid cancer has been decreasing and is now at 2.1 percent per year, but the incidence of thyroid cancer detection has increased by 45 percent per year over the past decade. Mortality rate has increased, but only by 0.7 deaths per 100,000 person years. In addition, the five-year survival rate is high, at 98.1 percent overall, varying between 99.9 percent for localized disease to 55.3 percent for distant disease. The results of the review showed there was inadequate direct evidence on the benefits of screening. The task force did determine, however, that the magnitude of the overall benefits of screening and treatment can be bounded as no greater than small, given the relative rarity of thyroid cancer, the apparent lack of difference in outcomes between patients who are treated vs monitored (for the most common tumor types), and observational evidence showing no change in mortality over time after introduction of a mass screening program. There was no inadequate direct evidence on the harms of screening but the task force determined the overall magnitude of the harms of screening and treatment can be bounded as at least moderate, given adequate evidence of harms of treatment and indirect evidence that over-diagnosis and over-treatment are likely to be substantial with population-based screening. The USPSTF, therefore, determined the net benefit of screening for thyroid cancer is negative. Given the findings, the USPSTF now recommends against screening for thyroid cancer in asymptomatic adults.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.